patients should not increase intracranial pressure (ICI') or change cerebral perfusion pressure (CPP) and cerebral blood flow. This doubleblind, cross-over study compares the effects of a single (3 x effective dose producing 95% twitch depression) intravenous bolus dose of cisatracurium 0.15 mg/kg with atracurium 0.75 mg/kg on mean red blood cell flow velocity in the middle cerebral artery (CBFV; transcranial Doppler), ICI' (intraventricular or intraparenchymal monitor), mean arterial pressure (MAP), CPP (MAP -IQ), and heart rate (HR) every minute during a 15-min study period. Included in the study were 14 sedated and ventilated adult neurosurgical patients. After the cisatracurium bolus, ICI', CPP, CBFV, MAP, and HR did not change, and no histamine related events were observed. After the atracurium bolus, IQ, CPP, CBFV, and MAP decreased. The lowest values of ICP (-16% of baseline), CPP (-5%), CBFV (-8%), and MAP (-7%) were recorded 2-4 min after the atracurium bolus injection. After this transient decrease,
MAP and CPP returned to baseline, whereas CBFV and ICI' transiently exceeded baseline values. The highest values of CBFV (5%) and ICI' (17%) were recorded 9-12 min after the atracurium bolus injection. Five patients showed a typical histamine response after atracurium, with a decrease in MAP and flushing. Excluding these five patients eliminated statistical significance in ICP, CPP, CBFV, and MAP differences. In conclusion, cisatracurium demonstrated fewer cerebral and cardiovascular hemodynamic side effects in sedated adult neurosurgical patients. Implications: This double-blind study in sedated and mechanically ventilated adult neurosurgical patients demonstrates that an intravenous bolus dose of the neuromuscular blocker cisatracurium results in less cerebral (intracranial pressure, cerebral perfusion pressure, middle cerebral artery blood flow velocity) and cardiovascular (blood pressure) hemodynamic side effects, compared with an equipotent dose of atracurium. (Anesth Analg 1998; 86:123-7) D rugs that do not increase or preferentially decrease intracranial pressure (ICI') or change cerebral perfusion pressure (CPP) and cerebral blood flow (CBF) are preferred for neurosurgery and neurocritical care. Patients with intracranial hypertension who are restless and difficult to ventilate, despite receiving sedatives and analgesics, may require neuromuscular blockade to prevent an increase in ICI' wa.
Cisatracurium, a new, intermediate-acting, nondepolarizing muscle relaxant, releases less histamine than atracurium (3, 4) . Hemodynamic side effects are minimal even at 8 times the effective dose producing 95% twitch depression (ED& (3). Moreover, cisatracurium produces up to one tenth of the plasma laudanosine concentrations reported after atracurium (5). Cisatracurium therefore could come closer to being the ideal neuromuscular blocking drug for neuroanesthesia and neurocritical care.
Because there are no previous studies of the effects of cisatracurium on cerebral dynamics in neurosurgical patients, we compared the effects of cisatracurium with those of atracurium on ICI', mean red blood cell flow velocity in the middle cerebral artery (CBFV), mean arterial pressure (MAP), CPP (MAP -ICI'), and heart rate (HR).
Methods
After approval from our ethics committee, 14 adult neurosurgical patients were included in the study after being screened for medical history, drug intake, and physical condition. Patients known or suspected to have neuromuscular disorders or metabolic diseases were excluded. Because osteoclastic trepanation interferes with the normal relationship between MAP and ICI', patients who had undergone this procedure were also excluded from the study.
The investigation was performed in the intensive care unit (ICU), on postoperative or conservatively treated patients, at least 6 h after the last administration of neuromuscular blockers. To avoid any impact of residual neuromuscular blockade during the study, only intermediate-acting muscle relaxants (vecuronium, rocuronium) were used for tracheal intubation during the prestudy period, and normal neuromuscular transmission was verified before the study. All patients received adequate sedation with a continuous intravenous (IV) infusion of l-3.5 pg * kg-i . h-i sufentanil and 0.08-0.18 mg * kg-' * h-l midazolam before and throughout the study periods to ensure unconsciousness. The lungs of all patients were mechanically ventilated in a volume-controlled mode to maintain normocapnia or slight hypocapnia (ETco, between 32 and 40 mm Hg) with an air/oxygen mixture (fraction of inspired oxygen 0.30-0.50). Ventilation variables and core temperature (35.9-37.1"(Z) were kept constant throughout the study periods.
The patients had a radial artery cannula, an intraventricular catheter (n = 6), or an intraparenchymal probe (n = 8) placed in situ for ICI' measurements. A mainstream ETco, sensor and a ~-MHZ transcranial Doppler probe were attached. CBFV was continuously monitored by using a transtemporal approach. The ultrasonic sample volume was focused on the proximal segment of the middle cerebral artery, and the probe was fixed using skin adhesive to maintain insonation position constant over time. We attempted to control and minimize confounding factors that could influence cerebral dynamics. For 1 h before the study, there were no changes in positioning or sedation, and no physiotherapy was performed. External stimuli, such as noise or touch, which could alter ICI' or CBF, were either avoided or held constant during the study. HR, MAP, ETcoz, ICI', and transcranial Doppler signal were allowed to stabilize for at least 5 min. The ICI' was considered stable when no fluctuations from the base level occurred, except oscillations produced by secondary effects from artificial ventilation. Thereafter, baseline (BL; time [t] = 0) variables and arterial blood samples for the measurement of baseline Pace, were obtained. The observer was blinded to the identity of two identical syringes, one containin 8 0.15 mg/kg (3 X ED,,) (6) cisatracurium (Nimbex ; Glaxo-Wellcome, Greenford, UK) and the other 0.75 mg/kg (3 X ED,,) (7) atracurium (Tracrium@; Glaxo-Wellcome, London, UK). The contents of one syringe were injected IV (immediately after collecting baseline data), and ICI', CBFV, MAP, ETcoz, and HR values were recorded every minute thereafter for 15 min (t = l-15). This was then repeated in a crossover design in a randomized sequence for the second syringe at least 6 h later. Possible histamine-related reactions, such as skin rashes, bronchospasm, or severe (exceeding 20% of baseline values) cardiovascular hemodynamic changes, and clinically adverse events were also recorded.
Analysis of variance for repeated measures was performed for ICI?, CPP, CBFV, MAP, ETcoz, and HR values for both investigations after normal data distribution was verified. Multiple comparison was performed by using Bonferroni-corrected paired t-tests when analysis of variance revealed significance. Baseline variables for both investigations were compared using Student's paired t-test. Results were considered statistically significant at two-tailed P values < 0.05. All data are expressed as mean +-SD.
Results
Baseline variables of the 14 patients aged 40 + 13 yr are presented in Table 1 . Nine patients had subarachnoidal hemorrhage resulting from cerebral aneurysm (five middle cerebral artery, three communicating anterior artery, one basilar artery). Two patients were admitted to the ICU after the evacuation of an intracerebral hematoma, another two patients with intracerebral hematomas were treated conservatively, and one patient had traumatic subarachnoid bleeding associated with an automobile accident. Baseline variables did not differ significantly between the two investigations. The time course of changes from baseline in ICI', CPP, CBFV, MAP, and HR values during the 15-min study periods is shown in Figure 1 . There were no significant changes in ICI', CPP, CBFV, MAP, ETcoz, and HR values after the 3 X ED,, cisatracurium bolus dose. No patient had histamine-related symptoms or experienced adverse clinical events, and there were no clinically relevant episodes of tachycardia, bradycardia, hypotension, and systemic or intracranial hypertension after the cisatracurium bolus injection.
After the 3 X ED,, bolus of atracurium, ICP, CPP, CBFV, and MAP values decreased. The lowest values of ICP (-16% of baseline), CPP (-So/,), CBFV (-8%), and MAP (-7%) were recorded 2-4 min after the atracurium bolus injection. After this transient decrease, MAP and CPP returned to baseline values, whereas CBFV and ICP transiently exceeded baseline values. The highest values of CBFV (5%) and ICP (17%) were recorded 9-12 min after the atracurium bolus injection. Again, there was no significant change in ETco,. A slight increase in HR did not reach statistically significance. Five patients exhibited a typical histamine response after the atracurium bolus, with a decrease in MAP and flushing. Statistical significance in ICI' (P = 0.0004), CPP (P = 0.0098), CBFV (P = 0.0003), and MAP (P = 0.0001) was eliminated when these five patients were excluded. However, none of the patients showed severe cardiovascular episodes, CPP never decreased below 50 mm Hg and ICP never increased above 26 mm Hg in any of the patients.
Discussion
To evaluate the usefulness of cisatracurium compared with atracurium in neurosurgical patients, we investigated the effects of these nondepolarizing neuromuscular blockers on IQ?, CPP, CBFV, MAP, and HR. Monitoring CBFV using transcranial Doppler provides continuous, noninvasive, real-time cerebral hemodynamic information. The Doppler probe was mechanically fixed throughout the study to eliminate investigator-dependent variability. We studied changes from baseline, rather than absolute values.
ANESTHESIA SCHRAMM ET AL. CISATRACURIUM, ATRACURIUM, 1998;86:123-7 Although the Doppler signal reflects red blood cell flow velocity and not nutritive CBF, changes in CBFV of the middle cerebral artery were shown to correlate reliably with changes in CBF (8). We decided to study IV bolus injection, rather than continuous IV infusions of the muscle relaxants, because this is the usual mode of muscle relaxation performed in the ICU to prevent increases in ICI' (2), especially for tracheal suction (1,2) . Long-term infusion of muscle relaxants, on the other hand, may increase the duration of ICU stay in head-injured patients (9) and may also be associated with an increased risk of pneumonia (9).
Comparing the responses after a single bolus dose of 3 X ED,, atracurium with those after an equipotent bolus dose of cisatracurium in sedated adult neurosurgical patients with slightly increased ICI', we found that cisatracurium had no significant and relevant effects on ICI', CPP, CBFV, and MAP values during a 15-minute study period. Histamine release is the principal mechanism by which the newer benzylisoquinolinium neuromuscular blocking drugs are thought to produce cardiovascular effects in humans. Because cisatracurium almost lacks histaminereleasing properties (3,4), as demonstrated in previous studies (lo), neither a substantial decrease in blood pressure nor tachycardia was likely to be seen. CPP is calculated as MAP -ICI', and because neither are influenced by cisatracurium, it becomes obvious that CPP was not impaired. CBFV also was not influenced by cisatracurium in our study, which suggests an unchanged CBF.
After the atracurium bolus, we observed significant changes in ICI', CPP, CBFV, and MAP values. Contrary to our results, many human and animal studies have shown that atracurium up to 2 X ED,, exerts no adverse effect on ICI' (11) (12) (13) (14) (15) (16) (17) (18) . It seems to be the other way around, because some studies even report that muscle relaxation could be advantageous to patients with intracranial hypertension (19), especially during tracheal suction (1). However, one study evaluating the effects of 4 X ED,, (1 mg/kg) atracurium administered to three neurosurgical patients with normal levels of consciousness for tracheal intubation reported ICI' increases above preinduction values (18) in one of the three patients, probably associated with tracheal stimulation.
ICI' increases after administration of d-tubocurarine (20) have been shown to result from both histamineinduced (cerebral) vasodilation and ganglionic block, both of which may produce arterial hypotension.
A decrease in MAP coupled with an increase in ICP could result in a substantial decrease in CPP. Furthermore, it has been reported that histamine itself has direct stimulating effects on the brain (21).
Atracurium also has the potential to release histamine (22,23), which may be accompanied by histamine-induced hypotension (22, 24) . Severe hypotension (25, 26) or decreases in systemic vascular resistance (25) have been observed after 2 X ED,, atracurium or less in some patients. However, the histamine-liberating potential of atracurium is considerably less than that of d-tubocurarine (23, 27) . The decrease in MAP after 6 X ED,, (1.5 mg/kg) atracurium can be prevented or diminished by pretreatment with a combination of Hl and H2 histaminic receptor blockers (24). In our study, no patient experienced histaminic receptor blockade because there was no history of atopy, allergy, or gastrointestinal bleeding in any of the patients. Moreover, H2 blockade may be associated with an increased risk of nosocomial pneumonia in ICU patients (28). Furthermore, de Jong et al. (29) demonstrated that atracuriuminduced vasodilation might not be mediated by histamine, because histamine receptor blockade in animals did not completely prevent decreases in MAP values . Evidence from animal models also suggests that laudanosine might contribute to transient MAP value decreases with the rapid IV administration of large doses of atracurium (30). Along with the decrease in MAP values after the bolus injection of atracurium, CPP and CBFV values also decreased. Thereafter, CBFV resulted in an overshoot to 5% of baseline level, probably because of an autoregulatory vasodilative response in remote, still normal cerebral arteries. These findings, along with the subsequent velocity regulation back to the prestudy level, illustrate the maintained responsiveness of still normal cerebrovascular beds (31). The decrease in CPP values in our patients was not large and, therefore, never alarming. Neither patient had obvious neurologic sequalae. However, in the presence of increased ICI' values, in which CPP already could be marginal, such a decrease may severely compromise CBFV and, consequently, CBF (8). The side effects of atracurium in our study were transient. In patients who are hemodynamically stable, with normal or only mildly decreased CPP, the use of atracurium should be of little concern, particularly if it is injected slowly, because the side effects of atracurium may be decreased by injection over 30 to 75 seconds (32). Therefore, despite its potential for histamine release and, theoretically, excitation of the central nervous system because of the degrading product laudanosine, atracurium has been extensively used for neuroanesthesia.
In conclusion, the results from this study suggest that 3 X ED,, atracurium as a bolus dose, could be disadvantageous to neurosurgical patients with increased ICI'. We conclude that compared with atracurium, cisatracurium seems to be a more appropriate neuromuscular blocking drug for use in adult neurosurgical patients under continuous sedation because of its greater cardiovascular stability without cerebral and cardiovascular hemodynamic side effects.
